YN203

YN203 is an investigational drug candidate developed by Guangzhou Yinnuo Pharmaceutical (Innogen) for the treatment of type 2 diabetes (T2D). It is designed to target the glucagon receptor (GCGR), a G protein-coupled receptor that plays a central role in glucose homeostasis by mediating the effects of glucagon on hepatic glucose production. While the specific functional activity—whether it acts as an agonist or an antagonist—has not been explicitly detailed in company disclosures, GCGR modulators are a significant area of research for metabolic diseases, typically aimed at reducing blood glucose levels. As of the current pipeline status, YN203 is in the preclinical stage of development.